Efavirenz
Non-Nucleoside Reverse Transcriptase Inhibitors
Sold as Sustiva · Stocrin · Atripla
- Drug class
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 4
- Products on record
- 23
- FDA reports (12 mo)
- 107
Overview
Efavirenz is an active pharmaceutical ingredient in the Non-Nucleoside Reverse Transcriptase Inhibitors group (J05AG). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 9 | May 15, 2026 |
| CA Canada | Health Canada | 8 | April 29, 2026 |
| EU European Union | EMA | 5 | November 18, 2025 |
| US United States | FDA | 1 | June 28, 2024 |
GBUnited Kingdom· MHRA
9 products
Uses
Efavirenz/Emtricitabine/Tenofovir Disoproxil film-coated tablets is a fixed- dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months.
1). 1). No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients. No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.
How to take
CACanada· Health Canada
8 products
Uses
AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 3 WARNINGS AND PRECAUTIONS .................................................................................
4 ADVERSE REACTIONS ................................................................................................. 11 DRUG INTERACTIONS .................................................................................................
17 DOSAGE AND ADMINISTRATION ............................................................................. 23 OVERDOSAGE................................................................................................................
24 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 24 STORAGE AND STABILITY ......................................................................................... 31 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................
EUEuropean Union· EMA
5 products
Uses
Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months.
1). 1). No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients. No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents
How to take
USUnited States· FDA
1 product
Uses
5 kg. ( 1 )
How to take
Drug interactions
Known interactions involving Efavirenz. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL363900397 · revised December 29, 2025
- [2]Health Canada (DPD) · 02389762 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/004240 · revised November 18, 2025
- [4]FDA DailyMed · 13ca3456-e5bf-4b… · revised June 28, 2024 [PDF]
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.